Business Context and Reporting Period
Company: Ionis Pharmaceuticals, Inc. (IONS)
Filing Type: Form 8-K (Current Report)
Date of Report: July 9, 2026
Reporting Period: Fiscal Year ending December 31, 2026
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a regulatory disclosure regarding financial guidance rather than a presentation of historical financial statements.
Material Changes
There are no material changes to the financial outlook reported in this filing. The Company is reaffirming its previously announced financial guidance for the fiscal year ending December 31, 2026, which remains unchanged from the guidance provided on April 29, 2026.
Guidance, Outlook, and Risks
- Guidance Reaffirmation: Management has confirmed that the 2026 financial guidance remains consistent with the Q1 2026 earnings release.
- Forward-Looking Statements: The report contains projections regarding 2026 financial performance. These are subject to risks inherent in drug discovery, development, and commercialization.
- Risk Factors: Potential deviations from projections may occur due to uncertainties in developing safe and effective human therapeutics. Detailed risks are referenced in the Company's 2025 Form 10-K and most recent Form 10-Q.
- Legal Disclaimer: Information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific numerical targets for 2026 revenue and expenses in the April 29, 2026, Q1 earnings release.
- Review the Form 10-K for the year ended December 31, 2025, for detailed risk factors affecting the guidance.
- Confirm the status of key clinical programs and commercialization efforts that underpin the 2026 financial projections.